Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]

Saved in:

Bibliographic Details
Published in	Acta pharmaceutica Sinica. B Vol. 13; no. 11; pp. 4664 - 4666
Main Authors	Wu, Canhao, Xu, Qin, Wang, Huiyuan, Tu, Bin, Zeng, Jiaxin, Zhao, Pengfei, Shi, Mingjie, Qiu, Hong, Huang, Yongzhuo
Format	Journal Article
Language	English
Published	Elsevier 01.11.2023
Online Access	Get full text

Cover

Loading…

Author	Xu, Qin Zhao, Pengfei Wang, Huiyuan Qiu, Hong Tu, Bin Huang, Yongzhuo Shi, Mingjie Wu, Canhao Zeng, Jiaxin
Author_xml	– sequence: 1 givenname: Canhao surname: Wu fullname: Wu, Canhao – sequence: 2 givenname: Qin surname: Xu fullname: Xu, Qin – sequence: 3 givenname: Huiyuan surname: Wang fullname: Wang, Huiyuan – sequence: 4 givenname: Bin surname: Tu fullname: Tu, Bin – sequence: 5 givenname: Jiaxin surname: Zeng fullname: Zeng, Jiaxin – sequence: 6 givenname: Pengfei surname: Zhao fullname: Zhao, Pengfei – sequence: 7 givenname: Mingjie surname: Shi fullname: Shi, Mingjie – sequence: 8 givenname: Hong surname: Qiu fullname: Qiu, Hong – sequence: 9 givenname: Yongzhuo surname: Huang fullname: Huang, Yongzhuo
BookMark	eNp9kcGO0zAQhiO0SCzLvgAnH-GQYI8TxzmhUi2w0goQBS4IWY49aV2lcWUnFXDqO3CFG0_WJyFp0UrLAV_GGvv_rPH3MDnrfIdJ8pjRjFEmnq0zvY11BhR4RmVGaXkvOQdgLOUy52e3e148SC5jXNNxCQpQFufJ79nQr3wgxoeApne-I70nh_3PNzj0Qbfuuz42fUMWs_eLdO4_pUC2EQfrdy4MkQzRdUsym19Bit3SdYgBLcGvY9pg2w6tDmSH0ZkW42H_i3yemV6TdysdNuOFoXdGk4XrpvKCMCBPxjngKWEF8MP-Bys4__Ioud_oNuLl33qRfHx59WH-Or15--p6PrtJDRSyTKHhBgyveM1yW0laMqyksbJpSiME5YIaFBWXLG-sKAytTSU0g5xbIW3BDL9Irk9c6_VabYPb6PBNee3UseHDUunQT5MoZo1lwDhK0eQNayoLHGtNeVUxCRUdWc9PrO1Qb9Aa7KbvvAO9e9K5lVr6nWJUcFnARIATwQQfY8DmNsyomsSrtZrEq0m8olKN4seQ_CdkXH9UOD7i2v9F_wCS3bk_
CitedBy_id	crossref_primary_10_1016_j_ajps_2025_101023
ContentType	Journal Article
Copyright	2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences
Copyright_xml	– notice: 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences
DBID	AAYXX CITATION 5PM DOA
DOI	10.1016/j.apsb.2023.08.007
DatabaseName	CrossRef PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	2211-3843
EndPage	4666
ExternalDocumentID	oai_doaj_org_article_1dcd1213e86f4f1f9d23eba039918290 PMC10638520 10_1016_j_apsb_2023_08_007
GroupedDBID	--- --K -05 -0E -SE -S~ 0R~ 1~5 4.4 457 4G. 53G 5VR 5VS 7-5 92M 9D9 9DE AAEDT AAEDW AAIKJ AALRI AAXUO AAYWO AAYXX ABKZE ABMAC ACGFS ACVFH ADBBV ADCNI ADEZE ADRAZ ADVLN AEUPX AEXQZ AFPUW AFUIB AGHFR AIGII AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AOIJS APXCP BAWUL BCNDV CAJEE CCEZO CIEJG CITATION DIK EBS EJD FDB GROUPED_DOAJ GX1 HH5 HYE HZ~ IPNFZ IXB JUIAU KQ8 M41 M48 O-L O9- OK1 Q-- R-E RIG ROL RPM RT5 SES SSZ T8U U1F U1G U5E U5O XH2 ~NG 5PM
ID	FETCH-LOGICAL-c2587-2f3c2c393b14d98071e98cd8ff7c660360ce693814fd65c0bc96a1243d68d51c3
IEDL.DBID	M48
ISSN	2211-3835
IngestDate	Wed Aug 27 01:29:15 EDT 2025 Thu Aug 21 18:36:21 EDT 2025 Thu Apr 24 23:10:39 EDT 2025 Tue Jul 01 01:53:12 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	11
Language	English
License	This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c2587-2f3c2c393b14d98071e98cd8ff7c660360ce693814fd65c0bc96a1243d68d51c3
Notes	erratum Equal contribution.
OpenAccessLink	http://journals.scholarsportal.info/openUrl.xqy?doi=10.1016/j.apsb.2023.08.007
PageCount	3
ParticipantIDs	doaj_primary_oai_doaj_org_article_1dcd1213e86f4f1f9d23eba039918290 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10638520 crossref_primary_10_1016_j_apsb_2023_08_007 crossref_citationtrail_10_1016_j_apsb_2023_08_007
ProviderPackageCode	CITATION AAYXX
PublicationCentury	2000
PublicationDate	2023-11-01
PublicationDateYYYYMMDD	2023-11-01
PublicationDate_xml	– month: 11 year: 2023 text: 2023-11-01 day: 01
PublicationDecade	2020
PublicationTitle	Acta pharmaceutica Sinica. B
PublicationYear	2023
Publisher	Elsevier
Publisher_xml	– name: Elsevier
SSID	ssj0000602275
Score	2.2676265
SourceID	doaj pubmedcentral crossref
SourceType	Open Website Open Access Repository Enrichment Source Index Database
StartPage	4664
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELZQT1wQlCIWSjUHVIFoILHz4xy3q1ZVJaqKbVElhCJ77EArtFltdiv1tu_AFW482T4JHjvb7nKAC9fEzo9nMvNlPPMNYy-lRlEUKos4KhGlAnUkrS0jk2eoBYUhfUD__Ul-dJ4eX2QXK62-KCcs0AOHhXuXGDREO2ZlXqd1UpeGC6tV7BxrQpuAZH2dz1v5mQo2mKjxKH-Rc-Lpczijq5gJyV1q3Oq31Dnc83dSL9kVr-TJ-_9MklzxOocP2YMOLkI_POYjds-ONtnuaeCbvtmDs7vyqXYPduH0jon65jH7RQGwZgJILTh8AQNMG1jMf5y4GRThCDWY0NQw7H8YRoPmY8Rh3NqZaa4vJ7MWKC3-C_QHBzyyHXOhNeAM-kRRyJ9yWOHatj63bjH_CZ_6OFXLpwiBchj62kvYh4TDK7ca_DU4dy4W8--EAj9vsfPDg7PBUdS1ZYiQZ84k8VogR1EKnaSmlA6j2FKikXVdYJ47jxijzUuHBNKaJB5rLHPlYIQwuTRZguIJ2xg1I_uUgVZJUeiCGHUwVaikQdrodSBS89iUaY8lS7FU2HGWU-uMb9UyOe2qIlFWJMqK-mnGRY-9uZ0zDowdfx29T9K-HUls2_6A08Gq08HqXzrYY3JNV9autn5mdPnVc3gnBBUzHj_7H_d_zu7TK4USyW22MZ3M7AuHlaZ6x38WvwE6bBKh priority: 102 providerName: Directory of Open Access Journals
Title	Author correction to “Neutralization of SARS-CoV-2 pseudovirus using ACE2-engineered extracellular vesicles” [Acta Pharmaceutica Sinica B 12 (2022) 1523–1533]
URI	https://pubmed.ncbi.nlm.nih.gov/PMC10638520 https://doaj.org/article/1dcd1213e86f4f1f9d23eba039918290
Volume	13
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9NAEF5V5cIFUR4iQKs5oApEXXl3_VgfEEqjVhWoVSENqoSQtS-XoioOdlKRW_4DV7jxy_JL2Fk7DUEVJy4-2F6_Znfn8-zM9xHyTCjN01TGAdOSBxHXKhDWZoFJYq04hiF9QP_oODkcRG_O4rM1spA7aj9gfeOvHepJDarL3W9fp6_dgH-1zNWSo1rtohC4p-PE4vJbzjOlqGhw1ML9ZmZGwjzMamQM2fsc-mjraG6-zIqv8pT-f6dO_uGLDu6SOy2IhG5j9Q2yZof3yPZJw0I93YHTZVFVvQPbcLLkp57eJ78wLFZWoFGYw5c1wLiE-ezHsWuBcY-mMhPKAvrd9_2gV34IGIxqOzHl1UU1qQGT5c-h29tngW35DK0BN81XEhcCMLMVrmztM-7ms5_wsavHcvEUTfgc-r4iE_aAMnjuvgZ7Ac7J8_nsO2LDTw_I4GD_tHcYtGINgWaxm6hYwTXTPOOKRiYTDrnYTGgjiiLVSeL8ZKhtkjl8EBXYD0Kls0Q6cMFNIkxMNX9I1ofl0D4ioCRNU5Uiz46OpJbCaFz-ddBSsdBkUYfQhVly3TKZo6DGZb5IWfuSoylzNGWOKpth2iEvr9uMGh6Pf569h9a-PhM5uP2OsjrP2yGdU6MNEuJZkRRRQYvMMG6VDB3ko7g83SFipa-sXG31yPDis2f2pgggYxY-_h_3f0Ju4ys1hZNPyfq4mthNh6DGastHHtz27Tux5YfIb0qJHR0
linkProvider	Scholars Portal
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Author+correction+to+%E2%80%9CNeutralization+of+SARS-CoV-2+pseudovirus+using+ACE2-engineered+extracellular+vesicles%E2%80%9D+%5BActa+Pharmaceutica+Sinica+B+12+%282022%29+1523%E2%80%931533%5D&rft.jtitle=Acta+pharmaceutica+Sinica.+B&rft.au=Canhao+Wu&rft.au=Qin+Xu&rft.au=Huiyuan+Wang&rft.au=Bin+Tu&rft.date=2023-11-01&rft.pub=Elsevier&rft.issn=2211-3835&rft.volume=13&rft.issue=11&rft.spage=4664&rft.epage=4666&rft_id=info:doi/10.1016%2Fj.apsb.2023.08.007&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_1dcd1213e86f4f1f9d23eba039918290
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2211-3835&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2211-3835&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2211-3835&client=summon